Philip Overend
About
Philip Overend is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology.
According to data from OpenAlex, Philip Overend has authored 29 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Immunology. Recurrent topics in Philip Overend's work include Lung Cancer Treatments and Mutations (6 papers), Chemokine receptors and signaling (4 papers) and Atherosclerosis and Cardiovascular Diseases (4 papers). Philip Overend is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Chemokine receptors and signaling (4 papers) and Atherosclerosis and Cardiovascular Diseases (4 papers). Philip Overend collaborates with scholars based in United Kingdom, United States and Australia. Philip Overend's co-authors include Sharon Bingham, Phil Davey, Mark H Harries, Stephen Hughes, Perdita L. Pugh, Julie Gray, Steven A. Sheardown, Derek C. Rogers, Evelyn Grau and Jonathan P. Hatcher and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Blood.
In The Last Decade
Philip Overend
28 papers receiving 2.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Philip Overend United Kingdom | 16 | 1.1k | 1.0k | 632 | 515 | 334 | 29 | 2.6k | ||
| Ajay Dhaka United States | 21 | 1.8k 1.6× | 926 0.9× | 1.1k 1.8× | 780 1.5× | 75 0.2× | 28 | 3.1k | ||
| Kelvin Y. Kwan United States | 24 | 2.7k 2.4× | 1.2k 1.2× | 1.5k 2.4× | 1.3k 2.5× | 165 0.5× | 45 | 4.4k | ||
| Sang Don Koh United States | 41 | 1.5k 1.3× | 1.0k 1.0× | 790 1.3× | 2.6k 5.1× | 88 0.3× | 108 | 5.6k | ||
| Christophe Altier Canada | 37 | 1.1k 0.9× | 1.4k 1.3× | 1.6k 2.5× | 2.3k 4.6× | 130 0.4× | 87 | 4.5k | ||
| Lucy F. Donaldson United Kingdom | 32 | 471 0.4× | 1.1k 1.1× | 1.1k 1.8× | 1.2k 2.3× | 193 0.6× | 79 | 3.3k | ||
| Derek C. Rogers United Kingdom | 24 | 1.2k 1.0× | 1.2k 1.2× | 1.8k 2.9× | 1.3k 2.5× | 503 1.5× | 35 | 4.3k | ||
| Takashi Ueda Japan | 31 | 1.3k 1.1× | 510 0.5× | 477 0.8× | 1.2k 2.4× | 63 0.2× | 92 | 3.0k | ||
| Shinya Ugawa Japan | 31 | 1.3k 1.2× | 463 0.4× | 476 0.8× | 1.4k 2.7× | 74 0.2× | 80 | 2.9k | ||
| Tohko Iida Japan | 16 | 1.4k 1.2× | 756 0.7× | 634 1.0× | 455 0.9× | 36 0.1× | 22 | 2.2k |
Countries citing papers authored by Philip Overend
Since
Specialization
Citations
This map shows the geographic impact of Philip Overend's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Overend with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Overend more than expected).
Fields of papers citing papers by Philip Overend
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Philip Overend. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Overend. The network helps show where Philip Overend may publish in the future.
Co-authorship network of co-authors of Philip Overend
This figure shows the co-authorship network connecting the top 25 collaborators of Philip Overend. A scholar is included among the top collaborators of Philip Overend based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Overend. Philip Overend is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
O’Kane, Grainne M., Teresa Macarulla, Fiyinfolu Balogun, et al.. (2022). Abstract CT126: A phase 2 trial of first-line AZD0171 + durvalumab and chemotherapy (CT) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and CD8+ T cell infiltration. Cancer Research. 82(12_Supplement). CT126–CT126.
2.
Johnson, Melissa L., Jan Cosaert, Gerald S. Falchook, et al.. (2019). A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 3098–3098.
3.
Donnellan, William B., Ehab Atallah, Adam S. Asch, et al.. (2019). A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy. Blood. 134(Supplement_1). 3919–3919.
4.
Ahn, Myung‐Ju, Dong‐Wan Kim, Byoung Chul Cho, et al.. (2017). Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. The Lancet Respiratory Medicine. 5(11). 891–902.
5.
Cho, Byoung Chul, Myung‐Ju Ahn, Jong-Seok Lee, et al.. (2017). Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.. Journal of Clinical Oncology. 35(15_suppl). 2069–2069.
6.
Boever, Erika H. De, Anthony Cahn, Nicholas Locantore, et al.. (2014). Efficacy and safety of an anti–IL-13 mAb in patients with severe asthma: A randomized trial. Journal of Allergy and Clinical Immunology. 133(4). 989–996.e4.
7.
Kurrasch, Regina, Judith C. Brown, Myron Chu, et al.. (2013). Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics. The Journal of Rheumatology. 40(7). 1089–1096.
8.
Catchpole, I., Volker Germaschewski, Jaimie Hoh Kam, et al.. (2013). Systemic Administration of Abeta mAb Reduces Retinal Deposition of Abeta and Activated Complement C3 in Age-Related Macular Degeneration Mouse Model. PLoS ONE. 8(6). e65518–e65518.
9.
Koopman, Gerrit, Daniëlla Mortier, Sam Hofman, et al.. (2008). Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian–human immunodeficiency virus viraemia with protein/DNA combination. Journal of General Virology. 89(2). 540–5533.
10.
Brown, Verity J., David S. Tait, Simon T. Bate, et al.. (2005). 5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology. 181(2). 253–259.
11.
Murphy, Nuala, David C. Grimsditch, Martin Vidgeon-Hart, et al.. (2005). Dietary Antioxidants Decrease Serum Soluble Adhesion Molecule (sVCAM‐1, sICAM‐1) but not Chemokine (JE/MCP‐1, KC) Concentrations, and Reduce Atherosclerosis in C57BL but Not ApoE*3 Leiden Mice Fed an Atherogenic Diet. Disease Markers. 21(4). 181–190.
12.
Hegyi, László, Paul Hockings, G. Martin Benson, et al.. (2004). Short term arterial remodelling in the aortae of cholesterol fed New Zealand white rabbits shown in vivo by high-resolution magnetic resonance imaging — implications for human pathology. Pathology & Oncology Research. 10(3). 159–165.
13.
Murphy, Nuala, K. Richard Bruckdorfer, David C. Grimsditch, et al.. (2003). Temporal Relationships Between Circulating Levels of CC and CXC Chemokines and Developing Atherosclerosis in Apolipoprotein E*3 Leiden Mice. Arteriosclerosis Thrombosis and Vascular Biology. 23(9). 1615–1620.
14.
Murphy, Nuala, David C. Grimsditch, Martin Vidgeon-Hart, et al.. (2002). Hypercholesterolaemia and circulating levels of CXC chemokines in apoE*3 Leiden mice. Atherosclerosis. 163(1). 69–77.
15.
Bingham, Sharon, et al.. (2001). Inhibition of Inflammation-Induced Thermal Hypersensitivity by Sumatriptan through Activation of 5-HT1B/1D Receptors. Experimental Neurology. 167(1). 65–73.
16.
Reavill, Charlie, et al.. (2000). Evaluation of the spontaneously hypertensive rat as a model of attention deficit hyperactivity disorder: acquisition and performance of the DRL-60s test. Behavioural Brain Research. 109(1). 27–35.
17.
Davis, John B., Julie Gray, Martin J. Gunthorpe, et al.. (2000). Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature. 405(6783). 183–187.
18.
Haynes, Andrea, Brian A. Jackson, Philip Overend, et al.. (1999). Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat. Peptides. 20(9). 1099–1105.
19.
Festing, Michael F. W., Vera Baumans, Robert D. Combes, et al.. (1998). Reducing the Use of Laboratory Animals in Biomedical Research: Problems and Possible Solutions. Alternatives to Laboratory Animals. 26(3). 283–301.
20.
Manser, C. E., Donald M. Broom, Philip Overend, & Tim Morris. (1998). Investigations into the preferences of laboratory rats for nest-boxes and nesting materials. Laboratory Animals. 32(1). 23–35.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ajay Dhaka Breakdown of academic impact, for papers by Kelvin Y. Kwan Breakdown of academic impact, for papers by Sang Don Koh Breakdown of academic impact, for papers by Christophe Altier Breakdown of academic impact, for papers by Lucy F. Donaldson Breakdown of academic impact, for papers by Derek C. Rogers Breakdown of academic impact, for papers by Takashi Ueda Breakdown of academic impact, for papers by Shinya Ugawa Breakdown of academic impact, for papers by Tohko Iida